YF17D vector based coronavirus vaccine / University of Leuven, Batavia Biosci - LARVOL DELTA

Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. (PubMed, EBioMedicine) - "Our findings warrant the development of YF-S0 as dual SARS-CoV-2 and YFV vaccine. Contrary to other viral vaccine platforms, use of YF17D does not suffer from pre-existing vector immunity."

Journal • Preclinical • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate. (PubMed, Mol Ther Methods Clin Dev) - "The transmission risk of YF-S0 was hence compared to readily transmitting YF-Asibi strain and non-transmitting YF17D vaccine, with no evidence for productive infection of mosquitoes. The overall favorable safety profile of YF-S0 is expected to translate to other vaccines based on the same YF17D platform."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • STAT2